Floatz logo

12 assets in Endometrium Adenocarcinoma

Therapeutic assets addressing Endometrium Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Capivasertib
Endometrium Adenocarcinoma
National Cancer Institute (NCI)P2B (60)
Olaparib
Endometrium Adenocarcinoma
National Cancer Institute (NCI)P2B (60)
Cediranib
Endometrium Adenocarcinoma
National Cancer Institute (NCI)P2B (59)
Durvalumab
Endometrium Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Endometrium Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Nivolumab
Endometrium Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Tislelizumab
Endometrium Adenocarcinoma
SOLTI Breast Cancer Research GroupP2CCC (53)
Apl-5125
Endometrium Adenocarcinoma
Apollo Therapeutics LtdP1/2CCC (48)
Pasifolate Exatecan
Endometrium Adenocarcinoma
Elucida OncologyP1/2CCC (48)
Spartalizumab
Endometrium Adenocarcinoma
SOLTI Breast Cancer Research GroupP2CC (46)
Amt-151
Endometrium Adenocarcinoma
Multitude Therapeutics Inc.P1CC (43)
Vistusertib
Endometrium Adenocarcinoma
M.D. Anderson Cancer CenterP1CC (43)